Universal Ibogaine (TSXV:IBO) EV-to-EBIT : -6.59 (As of May. 27, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Universal Ibogaine's Enterprise Value is C$6.80 Mil. Universal Ibogaine's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was C$-1.03 Mil. Therefore, Universal Ibogaine's EV-to-EBIT for today is -6.59.

The historical rank and industry rank for Universal Ibogaine's EV-to-EBIT or its related term are showing as below:

TSXV:IBO' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.94 Med: -1.96 Max: -0.55
Current: -6.59

During the past 7 years, the highest EV-to-EBIT of Universal Ibogaine was -0.55. The lowest was -7.94. And the median was -1.96.

TSXV:IBO's EV-to-EBIT is ranked worse than
100% of 424 companies
in the Biotechnology industry
Industry Median: 10 vs TSXV:IBO: -6.59

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Universal Ibogaine's Enterprise Value for the quarter that ended in Jan. 2024 was C$4.35 Mil. Universal Ibogaine's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was C$-1.03 Mil. Universal Ibogaine's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -23.70%.

Universal Ibogaine EV-to-EBIT Historical Data

The historical data trend for Universal Ibogaine's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine EV-to-EBIT Chart

Universal Ibogaine Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Jul22

Jul23

EV-to-EBIT

Get a 7-Day Free Trial

-24.13

-29.03

-24.30

-0.83

-2.39

Universal Ibogaine Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EV-to-EBIT	Get a 7-Day Free Trial															-0.89	-0.88	-2.39	-2.26	-4.22

Competitive Comparison of Universal Ibogaine's EV-to-EBIT

For the Biotechnology subindustry, Universal Ibogaine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's EV-to-EBIT falls into.

Universal Ibogaine EV-to-EBIT Calculation

Universal Ibogaine's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	6.798	/	-1.031
	=	-6.59

Universal Ibogaine's current Enterprise Value is C$6.80 Mil.
Universal Ibogaine's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.03 Mil.

Universal Ibogaine (TSXV:IBO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Universal Ibogaine's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2024 )	=	EBIT	/	Enterprise Value (Q: Jan. 2024 )
	=	-1.031	/	4.34994
	=	-23.70 %

Universal Ibogaine's Enterprise Value for the quarter that ended in Jan. 2024 was C$4.35 Mil.
Universal Ibogaine's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.03 Mil.

Universal Ibogaine EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Universal Ibogaine (TSXV:IBO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

IBOGF:USA JC4:Germany

Address

400 3rd Avenue South west, Suite 1470, Calgary, AB, CAN, T2P 4H2

Website

https://www.universalibogaine.com

Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

Universal Ibogaine (TSXV:IBO) Headlines

No Headlines